缓释心血管药物市场

发达国家心血管疾病的患病率和发病率持续上升，为心血管疾病治疗的开发者带来了挑战和机遇。心血管疾病的治疗药物大多是口服即刻製剂，但由于与药物安全性和患者依从性有关的问题，能够提高药物安全性和减少给药次数的製剂受到关注。

目录

• 缓释心血管药物
• 执行摘要
• 心血管治疗-市场力学
• 心脑血管用药情况
• 心血管临床治疗的未满足需求
• 推动心血管药物需求的因素
• 人口变化
• 不断发展的製药技术
• 管理式医疗计划
• 扩大自我管理
• 缓释技术
• 口语
• 先进的覆膜系统
• 珠子系统
• 双层平板电脑
• 三层平板
• 微型平板电脑
• 经皮
• 心血管缓释产品分析
• 心血管治疗药物商业化的因素
• CR 治疗的心血管部分
• 心绞痛
• 胆固醇管理
• 心律失常
• 高血压
• 外周动脉疾病
• 市场因素
• 监管和批准
• 美国 (FDA)
• 欧盟（欧洲、中东和非洲）
• 日本 (PMDA)
• 澳大利亚 (TGA)
• 管理式护理和医疗保健经济学
• 进入该行业的公司简介

The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers. While the vast majority of drugs for treating cardiovascular conditions are oral immediate release products, issues related to drug safety and patient compliance have focused attention on formulations that can improve drug safety profiles and reduce dosing frequency. Important treatment segments for controlled release cardiovascular drugs include angina, hypertension, arrhythmias, cholesterol, and peripheral artery disease. Important growth factors for controlled release cardiovascular drugs include evolving patient demographics, environmental and lifestyle causative factors, increased public awareness of cardiovascular conditions and their associated morbidities, and expanded patient access to cardiovascular treatment services.

What You Will Learn:

• Analyzes and evaluates controlled release cardiovascular drug products and assesses the market potential for existing and probable future products

• Analyzes product strategies, technologies and market development issues

• Provides detailed analysis of cardiovascular market segments, market demographics, and therapeutic strategies

• Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations

• Evaluates the impact of economic, technology, and regulatory factors on cardiovascular drug markets

Table of Contents

• Controlled Release Cardiovascular Therapeutics
• Executive Summary
• Cardiovascular Therapeutics - Market Dynamics
• The Cardiovascular Drug Landscape
• Unmet Needs in Cardiovascular Clinical Treatment
• Cardiovascular Drug Demand Drivers
• Demographic Shifts
• Evolving Drug Formulation Technology
• Managed Care Initiatives
• Growth in Self Administration
• Modified Release Technologies
• Oral
• Advanced Film Coating Systems
• Bead Systems
• Bi-layer Tablets
• Tri-layer Tablets
• Microtablets
• Transdermal
• Cardiovascular Controlled Release Product Analysis
• Cardiovascular Drug Commercialization Factors
• Cardiovascular Segments for CR Therapeutics
• Angina
• Cholesterol Management
• Heart Rhythm
• Hypertension
• Peripheral Artery Disease
• Market Factors
• Regulations and Approvals
• US (FDA)
• EU (EMEA)
• Japan (PMDA)
• Australia (TGA)
• Managed Care and Healthcare Economics
• Sector Participant Company Profiles